LDS/Medical Tests/Interleukin 28 B (IL28B) Gene Variation Analysis

Interleukin 28 B (IL28B) Gene Variation Analysis

Chronic hepatitis C virus infection is still a major cause for developing cirrhosis and hepatocellular carcinoma which often results in liver failure and thus in liver transplantation. Worldwide, 170 million people are infected with the hepatitis C virus (HCV), and it has become the most common cause of liver-related death in the United States.

While up to 80% of the genotype 2 and 3 infected patients can be cured using the standard of care treatment, the response rate is only 40–50% in genotype 1 infections.

Therapeutic treatment for HCV depends on both viral and host factors. For example, HCV genotype is an important viral determinant of response: patients infected with type 1 or 4 have lower sustained virological response (SVR) rates than those infected with type 2 or 3. It has been shown that the major difference in response to therapy is caused by gene variation on host responses and specifically in Interleukin 28 B (IL28B).

The most common gene variation in IL28B is the single nucleotide polymorphism (SNP) IL28B rs12979860. Based on this gene variation or SNP, three genotypes are seen: CC, CT, and TT. The frequency of these alleles vary widely across racial and ethnic groups, with the rs12979860 CC genotype being present in about 37% of Caucasian individuals, 14% of African American individuals and 29% of Hispanic individuals. The C/C genotype of interleukin 28B (IL28B) was shown to be associated with a better SVR then C/T and T/T genotypes. SNPs near the IL28B region are the strongest baseline predictors of a SVR to pegylated interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection.

The IL28B mutation analysis test is used to determine the rs12979860 genotype to help predict therapeutic response in HCV-infected patients who are being considered for treatment with pegylated interferon-α/ribavirin or other available anti HVC therapy.

  • Monitor HCV infection treatment response and therapy management
  • Predicting HCV disease outcome
Genotypes (individuals) with the *IL28B* rs12979860 CC variations have more favorable treatment response than those with the CT or TT genotypes. Since the treatment depends also on HCV genotyping, results from this testing should always be used in conjunction with HCV genotype test results.

IL 28B CC

Three possible genotypes: CC, CT, and TT

 

 

PCR and fluorescence monitoring, Real-time PCR allelic discrimination assay using fluorescent probes specific for the C and T alleles of the rs12979860 SNP, PCR with allele specific primer extension (ASPE) or ARMS.

Whole blood (EDTA). Buccal swab, 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
HCV viral load, HCV genotyping, HCV phenotyping, liver function panel, liver biopsy, acute hepatitis panel including HAV, HBV and HBE antibody testing.
3-7 days upon receipt.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login